At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Nov 4, 2026 at 16:02 ET
Revolution Medicines reported Q3 2026 results with RASONQUE net product revenue of $197.6M from its first five weeks of commercial availability following FDA approval in August 2026. Net loss widened to $407.5M from $305.2M a year ago, driven by higher R&D and SG&A costs. The company reiterated full-year 2026 GAAP operating expense guidance of $2.1B-$2.2B.
- RASONQUE net product revenue of $197.6M for Q3 2026, reflecting ~5 weeks of commercial availability
- FDA approved RASONQUE on August 26, 2026 for metastatic pancreatic cancer
- Positive CHMP opinion recommending EU approval received in October 2026
- Net loss of $407.5M in Q3 2026 vs $305.2M in Q3 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access